Recruiting
Investigational
Evaluation of Choline Chloride for Intestinal Failure Patients Receiving Long-Term Parenteral Support
Investigational
- Substances:–
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
Find therapies in clinical trials near you – page 54
- recruiting
- 3 977
- countries
- 28
- conditions
- 2 105
3 977 trials recruiting28 European countries2 105 conditions coveredUpdated today
3 664 trials match your criteria
Recruiting
Follicular lymphoma
RecruitingStudy Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma
Registered drugNo placebo
Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma
Registered drugNo placebo
- Disease:Follicular lymphoma
- Substances:CyclophosphamideGolcadomide+8
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Cyclophosphamide
Recruiting
Small intestine neuroendocrine tumour
RecruitingEfficacy of 177Lu-DOTATATE as Adjuvant Therapy After Surgery for Stage III Small Intestinal Neuroendocrine Tumors
Registered drugNo placebo
Efficacy of 177Lu-DOTATATE as Adjuvant Therapy After Surgery for Stage III Small Intestinal Neuroendocrine Tumors
Registered drugNo placebo
- Disease:Small intestine neuroendocrine tumour
- Substances:Lutetium (177LU) oxodotreotide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Lutetium (177LU) oxodotreotide
Recruiting
Hepatitis D
RecruitingClinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments
Registered drugNo placebo
Clinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments
Registered drugNo placebo
- Disease:Hepatitis D
- Substances:BJT-778Bulevirtide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:BJT-778
Recruiting
Neuroblastoma
RecruitingStudy of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma
Registered drugNo placebo
Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma
Registered drugNo placebo
- Disease:Neuroblastoma
- Substances:BevacizumabDinutuximab Beta+3
Countries:Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:Bevacizumab
Recruiting
Obesity+2
RecruitingStudy on Tirzepatide for Women with Overweight or Obesity and Polycystic Ovary Syndrome (PCOS)
Registered drug
Study on Tirzepatide for Women with Overweight or Obesity and Polycystic Ovary Syndrome (PCOS)
Registered drug
- Disease:ObesityOverweight+1
- Substances:DydrogesteroneGlucose+2
Countries:Germany
Germany- Participants:18–64 years
- Substances:Dydrogesterone
Recruiting
Giant cell arteritis
RecruitingStudy on the Effectiveness of Abatacept for Patients with Giant Cell Arteritis
Investigational
Study on the Effectiveness of Abatacept for Patients with Giant Cell Arteritis
Investigational
- Disease:Giant cell arteritis
- Substances:Abatacept
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Abatacept
Recruiting
Dermatitis atopic
RecruitingEffectiveness and Safety of Abrocitinib in Children 6 to Under 12 Years with Moderate-to-Severe Atopic Dermatitis
Investigational
Effectiveness and Safety of Abrocitinib in Children 6 to Under 12 Years with Moderate-to-Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:Abrocitinib
Countries:Germany
Germany- Participants:0–17 years
- Substances:Abrocitinib
Recruiting
Malignant melanoma
RecruitingVusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments
Registered drugNo placebo
Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments
Registered drugNo placebo
- Disease:Malignant melanoma
- Substances:Dacarbazine CitrateNivolumab+5
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Dacarbazine Citrate
Recruiting
Endometrial cancer
RecruitingStudy of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients
Registered drugNo placebo
Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients
Registered drugNo placebo
- Disease:Endometrial cancer
- Substances:CarboplatinDocetaxel+6
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Carboplatin
Recruiting
Head and neck cancer
RecruitingStudy of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy
Registered drugNo placebo
Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy
Registered drugNo placebo
- Disease:Head and neck cancer
- Substances:CetuximabHafnium oxide
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Cetuximab
Recruiting
Short stature
RecruitingStudy on the Effects of Vosoritide for Children with Idiopathic Short Stature
Registered drug
Study on the Effects of Vosoritide for Children with Idiopathic Short Stature
Registered drug
- Disease:Short stature
- Substances:Vosoritide
Countries:Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:Vosoritide